RA
PETX

Royce & Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

Royce & Associates’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,200
Closed -$56K – 1216
2018
Q4 		$56K Hold
9,200
– – ﹤0.01% 1017
2018
Q3 		$54K Buy
+9,200
New +$46K ﹤0.01% 1048

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $432M AUM 42.58% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Royce & Associates's PETX Position: Q1 2019 in Review

Royce & Associates sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 9,200 shares — an estimated $56K sold.

Royce & Associates first reported a position in PETX in Q3 2018 and held it in 2 quarters. The position peaked at $56K in Q4 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • Royce & Associates reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Royce & Associates sold 9,200 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $56K.
  • Royce & Associates first reported a position in Aratana Therapeutics, Inc. in Q3 2018 and held it in 2 quarters.
  • Royce & Associates's Aratana Therapeutics, Inc. position peaked at $56K in Q4 2018.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Royce & Associates's 13F filing for Q1 2019, filed 9 May 2019.